Danaher (NYSE:DHR) Price Target Lowered to $265.00 at The Goldman Sachs Group

Danaher (NYSE:DHR) had its price target reduced by The Goldman Sachs Group from $270.00 to $265.00 in a research note released on Thursday,MarketScreener reports. They currently have a buy rating on the conglomerate’s stock.

Several other research firms have also weighed in on DHR. Rothschild Redb lowered shares of Danaher from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 8th. Jefferies Financial Group lifted their price target on shares of Danaher from $255.00 to $265.00 and gave the stock a “buy” rating in a research report on Wednesday. Morgan Stanley assumed coverage on shares of Danaher in a research report on Monday, December 1st. They issued an “overweight” rating and a $270.00 price objective for the company. Evercore ISI reissued an “outperform” rating and issued a $254.00 target price on shares of Danaher in a research note on Wednesday. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Danaher in a research report on Monday, December 29th. Twenty research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat, Danaher has an average rating of “Moderate Buy” and a consensus price target of $252.32.

Danaher Trading Up 0.4%

DHR traded up $0.77 during trading on Thursday, reaching $220.39. 786,222 shares of the company’s stock were exchanged, compared to its average volume of 3,659,385. The company’s fifty day moving average price is $230.77 and its 200-day moving average price is $213.81. The firm has a market capitalization of $155.68 billion, a PE ratio of 43.58, a P/E/G ratio of 3.42 and a beta of 0.89. Danaher has a fifty-two week low of $171.00 and a fifty-two week high of $242.80. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.10 and a current ratio of 1.87.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Wednesday, January 28th. The conglomerate reported $2.23 EPS for the quarter, topping analysts’ consensus estimates of $2.14 by $0.09. Danaher had a return on equity of 10.81% and a net margin of 14.71%.The business had revenue of $6.84 billion during the quarter, compared to analysts’ expectations of $6.79 billion. During the same period in the previous year, the firm earned $2.14 earnings per share. The firm’s quarterly revenue was up 4.6% compared to the same quarter last year. Danaher has set its FY 2026 guidance at 8.350-8.500 EPS. As a group, equities analysts forecast that Danaher will post 7.63 EPS for the current year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 30th. Shareholders of record on Friday, December 26th will be given a dividend of $0.32 per share. The ex-dividend date of this dividend is Friday, December 26th. This represents a $1.28 annualized dividend and a yield of 0.6%. Danaher’s payout ratio is 26.39%.

Insider Activity

In other Danaher news, SVP Georgeann Couchara sold 5,174 shares of the business’s stock in a transaction that occurred on Monday, November 10th. The stock was sold at an average price of $210.42, for a total transaction of $1,088,713.08. Following the transaction, the senior vice president owned 2,625 shares of the company’s stock, valued at $552,352.50. The trade was a 66.34% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Teri List sold 3,298 shares of the company’s stock in a transaction that occurred on Tuesday, November 18th. The stock was sold at an average price of $226.50, for a total value of $746,997.00. Following the sale, the director owned 20,762 shares in the company, valued at approximately $4,702,593. This represents a 13.71% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 30,248 shares of company stock worth $6,609,663 in the last quarter. Corporate insiders own 11.10% of the company’s stock.

Institutional Trading of Danaher

Several institutional investors and hedge funds have recently added to or reduced their stakes in DHR. Elevated Capital Advisors LLC bought a new position in Danaher during the fourth quarter worth about $26,000. JPL Wealth Management LLC bought a new position in shares of Danaher during the 3rd quarter worth approximately $25,000. WFA of San Diego LLC acquired a new position in shares of Danaher during the 2nd quarter worth approximately $26,000. ANTIPODES PARTNERS Ltd bought a new stake in Danaher in the 3rd quarter valued at $27,000. Finally, Howard Hughes Medical Institute bought a new position in Danaher during the second quarter worth $27,000. 79.05% of the stock is owned by institutional investors.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.